Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Pro-PEG3-BA |
Mechanism EGFR L858R modulators(EGFR exon 21 L858R mutation modulators), EGFR T790M inhibitors(EGFR T790M inhibitors), EML4-ALK inhibitors(EMAP Like 4-Anaplastic lymphoma kinase fusion inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Discovery | CN | 12 Aug 2024 |